A 2024 study published in the American Journal of Health-System Pharmacy found no significant differences in weight loss outcomes between patients using compounded versus brand name semaglutide over 24 weeks of treatment (Thompson et al., 2024)
The doublespeak triggered some backlashnot only because the company is, in fact, capitalizing on the $15 billion weight-loss drug market, but because the company also didnt explicitly mention in the voiceover that it sells the compounded version of these medications (made by combining, mixing, or altering ingredients), which arent approved by the FDA
Patients Seeking Sustained, Proven Efficacy: With 72-week and 3-year data available from SURMOUNT-1, Tirzepatide offers a well-established track record of sustained results
Coming Soon
Provides home delivery with fast response for orders over AED 490
One of the key criteria for classifying an herb as an adaptogen is that it holds Generally Recognized As Safe (GRAS) status